Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00231400 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pompe Disease Registry Protocol

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Minor Study sites revised (272)v50 Show moreShow less
  2. Minor Study sites: 271 to 272v49
  3. Minor Study sites: 272 to 271v48
  4. Minor Site details revised at 2 of 272 sitesv47
  5. Minor Study sites: 271 to 272v46
Show 44 earlier versionsHide 44 earlier versions
  1. Minor Study sites revised (271)v45 Show moreShow less
  2. Minor Study sites: 275 to 271v44
  3. Minor Study sites revised (275)v43 Show moreShow less
  4. Minor Study sites: 212 to 275v42
  5. Minor Study sites: 275 to 212v41
  6. Minor Study sites revised (275)v40 Show moreShow less
  7. Minor Site details revised at 1 of 275 sitesv39
  8. Minor Site details revised at 1 of 275 sitesv38
  9. Minor Study sites revised (275)v37 Show moreShow less
  10. Minor Study sites revised (275)v36 Show moreShow less
  11. Minor Study sites: 274 to 275v35
  12. Minor Site details revised at 2 of 274 sitesv34
  13. Minor Site details revised at 1 of 274 sitesv33
  14. Minor Study sites: 272 to 274v32
  15. Minor Study sites: 270 to 272v31
  16. Minor Study sites: 191 to 270v30
  17. Minor Eligibility criteria expanded, about 27 words Study description expanded, about 7 words · Study title expanded, about 1 wordv29 Show all 3 changesShow less
    • Study description expanded, about 7 words
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  18. Minor Study sites: 190 to 191 Start date: Aug 21, 2004 to Sep 15, 2004v28 Show all 2 changesShow less
    • Start date: Aug 21, 2004 to Sep 15, 2004
  19. Minor Study sites: 50 to 190v27
  20. Notable Primary and study completion dates: Sep 30, 2022 to Jan 31, 2034v26
  21. Minor Publications: 2 to 5v25 Show moreShow less
  22. Notable Primary and study completion dates: Sep 30, 2026 to Sep 30, 2022v24
  23. Notable Primary and study completion dates: Sep 2022 to Sep 30, 2026 Start date: Sep 2004 to Aug 21, 2004v23 Show all 2 changesShow less
    • Start date: Sep 2004 to Aug 21, 2004
  24. Notable Primary and study completion dates: Sep 2021 to Sep 2022v22
  25. Minor Study sites: 1 to 50v21
  26. Minor Re-verified, no change to tracked fieldsv20
  27. Minor Eligibility criteria expanded, about 2 wordsv19 Show moreShow less
  28. Minor Study description shortened, about 46 wordsv18 Show moreShow less
  29. Minor Re-verified, no change to tracked fieldsv17
  30. Minor Enrollment target: 2000 Primary and study completion dates: Sep 2021v16 Show all 2 changesShow less
    • Primary and study completion dates: Sep 2021
  31. Minor Study description shortened, about 1 wordv15 Show moreShow less
  32. Minor Eligibility criteria shortened, about 4 wordsv14 Show moreShow less
  33. Minor 3 versions Re-verified since Jul 31, 2009, no change to tracked fieldsv11-v13
  34. Minor Enrollment target: 99999 to not statedv10
  35. Minor Re-verified, no change to tracked fieldsv9
  36. Minor Enrollment target: 99999v8
  37. Minor 3 versions Re-verified since Jun 28, 2007, no change to tracked fieldsv5-v7
  38. Minor Study sites: 5 to 1 Study description expanded, about 47 wordsv4 Show all 2 changesShow less
    • Study description expanded, about 47 words

    See this version in full on ClinicalTrials.gov ↗

  39. Minor Re-verified, no change to tracked fieldsv3
  40. Minor Study title expanded, about 1 wordv2 Show moreShow less
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
284 trials monitored
See 12 trials at risk
The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research related purposes. The objectives of the Registry are: * To enhance understanding of the variability, progression, identification, and natural history of Pompe disease, with the ultimate goal of better guiding and assessing therapeutic intervention. * To assist the Pompe medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care. * To characterize the Pompe disease population. * To evaluate the long-term effectiveness of alglucosidase alfa.
Trial Details
NCT Number NCT00231400
Lead Sponsor Genzyme, a Sanofi Company
Conditions Glycogen Storage Disease Type II, Pompe Disease
Enrollment 2,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov